Current CommentaryEvidence-Based Medicine and Fetal Treatment How to Get InvolvedChescheir, Nancy C. MD; D’Alton, Mary MDAuthor Information From the Departments of Obstetrics and Gynecology, Vanderbilt University School of Medicine, Nashville, Tennessee; and Columbia University, New York, New York. Corresponding author: Nancy Chescheir, MD, R 1217 MCN, Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN 37232; e-mail: [email protected]. Obstetrics & Gynecology: September 2005 - Volume 106 - Issue 3 - p 610-613 doi: 10.1097/01.AOG.0000174584.72261.b6 Buy Metrics AbstractIn Brief The Management of Myelomeningocele Study is a multicenter randomized controlled trial of in utero compared with postnatal repair of isolated spina bifida. Referral of potential patients to the Management of Myelomeningocele Study trial will provide the pregnant woman with substantial information about the fetal condition as well as the trial. The referral rate has been very slow. Possible reasons for this are physicians’ and the public’s belief that in utero surgery has already been proven to be better than postnatal repair or conversely to offer no benefit over standard therapy; that the trial does not address fundamental issues of maternal and fetal outcomes and safety; and that trial is not well designed. These beliefs are ill-founded. The practicing obstetrician has a fundamental role to inform potential patients about this and other research trials. Obstetricians have the opportunity to refer patients to a major clinical trial that has the potential to determine whether antenatal or postnatal spina bifida repair is optimal. © 2005 by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.